The mechanism of the drug action is similar to a Trojan horse, penetrating the cancer cells and kill them from the inside.
Innovative drug called titcomb-vedotin (tisotumab vedotin, TV) releases a toxic substance, destroying cancer cells from within. The results were so positive that the researchers moved to the second phase of testing for cervical cancer and other cancers, informs Rus.Media.
A new type of cancer drugs that acts as a Trojan horse, penetrating inside tumor cells, has demonstrated promising results among patients with six different types of cancer. More than a quarter of patients with advanced, resistant to treatment tumors of the cervix and bladder, and nearly fifteen percent with ovarian tumors and lungs were susceptible to the new method.
A team of scientists from the London Institute of cancer research and Royal Marsden Foundation NHS Foundation conducted a global clinical study of the first and second phases among the nearly 150 patients with different types of cancer who have stopped responding to standard treatment. Experts have identified that a significant number of patients with cancer were sensitive to the drug: their tumors or decreased, or ceased to grow. The results are published in the journal the Lancet Oncology.
“The most interesting in the open method of treatment – the fact that its mechanism of action is brand new. The method is similar to a Trojan horse, penetrating the cancer cells and kill them from the inside. Our study shows that the drug is able to treat a large number of people with different types of cancer and has manageable side effects,” – says one of the study’s authors, Professor Johann De Bono (de Bono, Johann).
During the tests, the researchers observed the response of 27 percent of patients with bladder cancer, 26.5% with cervical cancer, 14% with ovarian cancer, 13% with cancer of the esophagus, 13 percent with non-small cell lung cancer and seven percent with endometrial cancer. The reaction lasted on average 5.7 months, and some up to 9.5 months. The main side effects reported in the study, was bleeding from the nose, fatigue, nausea and discomfort of view, although the extent of the latter soon managed to reduce.
The drug consists of the toxic substance attached to the tail part of an antibody that is designed to search for receptor, called “tissue factor”, it is present in large quantities on the surface of many cancer cells and reduce the survival rate. Binding to tissue factor attracts medication to the cancer cells where they can kill them from the inside.
In the beginning of the study participated in only 27 patients to assess the safety and determine the correct dose, and then, realizing that medications are safe, researchers have increased that number by 120 people to find out impressive the drug need a purpose and how it affects the tumor. In the majority of patients participating in the study were diagnosed with late stage cancer, spread locally or around the body, which had already been treated, and therefore became resistant to an average of three different types of therapy.
Now TV is tested relative to other types of cancer, including bowel, pancreas, brain and neck, as well as the study of the second phase as a second-line treatment for cancer of the cervix.